Organon Believes It Can Beat Out Other Humira Rivals In US

PBMs Likely To List ‘Two Or Three’ Adalimumab Biosimilars On Formulary

 
• By David Wallace
  
Red Chess Pawn Standing Out From Row Of Black Pawns
Organon thinks it can stand out from the competition on adalimumab • Source: Shutterstock

More from Biosimilars

More from Products